COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,637 Articles (22,913 medRxiv, 8,724 bioRxiv)

Most recent first Previous |  Page 1257: Articles 12561-12570  | Next

SARS-CoV-2 spike-specific memory B cells express markers of durable immunity after non-severe COVID-19 but not after severe disease
Reyes, R., Clarke, K., Gonzales, S. J., Cantwell, A. M., Garza, R., Catano, G., Tragus, R. E., Patterson, T. F., Bol, S., Bunnik, E. M.
10.1101/2021.09.24.461732 — Posted: 2021-09-27
Spike independent replication of human coronavirus in bat cells
Linster, M., Mah, M. G., Low, D. H., Yan, Z., Jayakumar, J., Samsudin, F., Wong, F. Y., Bond, P. J., Mendenhall, I. H., Su, Y. C., Smith, G. J.
10.1101/2021.09.18.460924 — Posted: 2021-09-27
Effect of different disease-modifying therapies on humoral response to BNT162b2 vaccine in Sardinian multiple sclerosis patients
Pitzalis, M., Idda, M. L., Lodde, V., Loizedda, A., Lobina, M., Zoledzwieska, M., Virdis, F., Delogu, G., Pirinu, F., Marini, M. G., Mingoia, M., Frau, J., Lorefice, L., Fronza, M., Carmagini, D., Carta, E., Orru, V., Uzzau, S., Solla, P., Loi, F., Devoto, M., Steri, M., Fiorillo, E., Floris, M., Zarbo, I. R., Cocco, E., Cucca, F.
10.1101/2021.09.26.21264067 — Posted: 2021-09-27
Intravenous Immunoglobulin (IVIG) in Treating Non-ventilated COVID-19 Patients with Moderate to Severe Hypoxia is Pharmacoeconomically Favorable When Appropriately Targeted
Poremba, M., Dehner, M., Perreiter, A., Semma, A., Mills, K., Sakoulas, G.
10.1101/2021.09.26.21264152 — Posted: 2021-09-27
Clinician and patient experience of neurology telephone consultations during the COVID-19 pandemic
Nakornchai, T., Conci, E., Hensiek, A., Brown, J. W. L.
10.1101/2021.09.26.21264141 — Posted: 2021-09-27
Household Density and Influences from Family and Friends Shape Vaccine Intent Among Latino Families in the San Francisco Bay Area
Wojcicki, J., Escobar, M., De Castro Mendez, A., Martinez, S.
10.1101/2021.09.25.21264120 — Posted: 2021-09-27
Racial and ethnic inequalities in COVID-19 mortality within carceral settings: An analysis of Texas prisons and jails
Marquez, N., Moreno, D., Klonsky, A., Dolovich, S.
10.1101/2021.09.26.21264145 — Posted: 2021-09-27
Contact surveys reveal heterogeneities in age-group contributions to SARS-CoV-2 dynamics in the United States
Chin, T., Feehan, D. M., Buckee, C. O., Mahmud, A. S.
10.1101/2021.09.25.21264082 — Posted: 2021-09-27
pIVW: A novel Mendelian Randomization Method Accounting for Weak Instruments and Horizontal Pleiotropy with Applications to the COVID-19 Outcomes
Xu, S., Fung, W. K., Liu, Z.
10.1101/2021.09.25.21264115 — Posted: 2021-09-27
Descriptive characteristics of continuous oximetry measurement in moderate to severe COVID-19 patients
Sobel, J. A., Levy, J., Almog, R., Reiner Benaim, A., Miller, A., Eytan, D., Behar, J. A.
10.1101/2021.09.26.21264135 — Posted: 2021-09-27 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).